Quality-of-Life Outcomes in Patients who Underwent Subcutaneous Immunotherapy and Sublingual Immunotherapy in a Real-World Clinical Setting

Schwanke, Theresa; Carragee, Eugene J.; Bremberg, Maria G.; Reisacher, William R.

doi:10.2500/ajra.2017.31.4465

Cited by 15 publications

(13 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nowadays, few observational studies, under clinical routine conditions, have shown the benefits of AIT treatment in improving the QoL of patients with AR (38,39). Interestingly, Schwanke et al (40) in 2017 published a observational study with the objective to compare changes in QoL with sublingual immunotherapy (SLIT) and SCIT treatments in patients with AR in a real-world clinical setting. They concluded that although improvements in QoL were noted in both groups, changes in overall scores and the majority of domains only achieved statistical significance in the SCIT group.…”

Section: Discussionmentioning

confidence: 99%

Quality of life improvement with allergen immunotherapy treatment in patients with rhinoconjunctivitis in real life conditions. Results of an observational prospective study (ÍCARA)

Cuesta‐Herranz

Laguna²,

Mielgo

et al. 2019

Eur Ann Allergy Clin Immunol

View full text Add to dashboard Cite

Quality of life improvement with allergen immunotherapy treatment in patients with rhinoconjunctivitis in real life conditions. Results of an observational prospective study (ÍCARA) SummaryObjectives. Evaluate the changes in quality of life of patients with allergic rhinoconjunctivitis (AR), with or without asthma, after one-year treatment with allergen immunotherapy. Methods. This was an observational prospective multicenter study. RQLQ questionnaire and VAS scale to assess treatment satisfaction were used. Impact on AR and asthma was also analyzed. Any adverse reaction was recorded. Results. 127 patients were recruited. Mean values in RQLQ decreased from 2.61 to 1.34 points, reflecting a statistically and clinically significant improvement (p < 0.01). The percentage of asthmatic patients decreased significantly (p < 0.01). Mean value of patients' satisfaction was 7.24 (SD = 1.90). Only 11 patients presented systemic reactions (9.17%), none of them serious. Conclusions. One-year AIT treatment significantly increases QoL in patients with AR. Moreover, high patients' satisfaction values were reported, together with an adequate safety profile.conjunctivitis quality of life questionnaire; SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy; STROBE, Strengthening the reporting of observational studies in epidemiology; VAS, Visual analogue scale.

show abstract

Section: Discussionmentioning

confidence: 99%

Quality of life improvement with allergen immunotherapy treatment in patients with rhinoconjunctivitis in real life conditions. Results of an observational prospective study (ÍCARA)

Cuesta‐Herranz

Laguna²,

Mielgo

et al. 2019

Eur Ann Allergy Clin Immunol

View full text Add to dashboard Cite

show abstract

“…After 1 year of treatment, both SCIT and SLIT achieved the minimally important difference from baseline in the overall RQLQ score (33). Economic aspects have increasing importance in any medical treatment.…”

Section: Other Issues Investigatedmentioning

confidence: 95%

Allergic reactions after vaccination: translating guidelines into clinical practice

Incorvaia

Barberi

Pastorello

et al. 2019

Eur Ann Allergy Clin Immunol

View full text Add to dashboard Cite

Real-life studies offer the opportunity of obtaining outcomes suitable in clinical practice, as controlled trials do not mirror the real patients' population observed in clinical practice. This concept is particularly appropriate for allergen immunotherapy (AIT). Therefore, the current review will present and discuss the most recent and relevant studies published on this topic. Globally, 15 real-life studies on AIT efficacy are available until now, the total of patients amounts to 9090, with an average number of 699 patients per study. This high number significantly decreases the possibility that the observations from real-life study are casual, and confers to such studies a key role in the next years to assess issues other than efficacy and safety, especially those scantly investigated thus far.sessed by meta-analyses, but the validity and applicability of the observations resulting from RCTs data, especially in the context of real-life settings, is debatable (5). To confirm the applicability to common practice of AIT products demonstrated as effective in RCTs, real-life (also defined real-world) studies are needed. This model was increasingly used in recent years and, especially when based on large populations of patients, provides very useful data to optimize the prescription and the performance of AIT in clinical practice. Here, we will discuss the significance of the outcomes that were achieved in such studies.

show abstract

“…The authorized and Sinicized RQLQ was applied. RQLQ consists of 28 questions on a 7-point scale (0 = not impaired at all, 6 = severely impaired) in 7 domains: activity limitations, sleep problems, nose and eye symptoms, non-nose/eye symptoms, practical problems, and emotional functions [14]. Total score and seven domain scores between groups were compared.…”

Section: Secondary Outcomesmentioning

confidence: 99%

Efficacy of Bimin Decoction on patients with perennial allergic rhinitis: an open-label non-inferiority randomized controlled trial

Zhao

Yan

Gai

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Allergic rhinitis (AR) is a common allergic disease which affects people worldwide and traditional Chinese medicine is getting popular among AR patients for definite clinical effect and less adverse reactions. Lung qi deficiency and cold syndrome (LQDCS) is a frequent type of AR, and Chinese herbal medicine Bimin Decoction (BMD) was generated for AR patients with LQDCS. This study aimed to compare the clinical efficacy of BMD for AR patients with LQDCS to conventional medicine loratadine and fluticasone nasal spray. Methods/Design: The study was designed as an open-label, non-inferiority, randomized controlled trial. A total of 108 AR patients with LQDCS aged 19 to 60 were 1:1 randomly allocated to BMD group and control group by central computer system in Beijing Hospital of Traditional Chinese Medicine from January 2017 to April 2018. 98 completed the study (n=51; n=47). Patients in BMD group received Bimin Decoction while the control group received fluticasone nasal spray and loratadine tablets for a 4-week treatment. The primary outcome was change of the Total Nasal Symptom Score (TNSS) at baseline and the end of treatment. Alterations in Rhinoconjunctivitis Quality Life quality Questionnaire (RQLQ), nasal resistance (NR) and acoustic rhinometry parameters were second outcomes. Any side effect of treatment was observed and recorded. Results: After the 4-week treatment the TNSS total score was significantly reduced in both groups from baseline ( P < 0.05), no significant between-groups differences were observed for the changes of TNSS scores [-0.298 (95% CI -0.640 to 0.140)], which was within the defined non-inferiority margin. RQLQ in both groups decreased significantly ( P < 0.001) from baseline and more obvious reduction in BMD group was observed ( P < 0.001). There was no significant difference in the nasal resistance, the nasal volume and the nasal minimum cross-sectional area after treatment between groups ( P > 0.05). Conclusions: These findings indicated that BMD helps relieve PAR symptoms and improve rhinitis-related life quality. Our study indicated that BMD is non-inferior to loratadine tablets and fluticasone nasal spray for AR patients with LQDCS. Trial registration: Chinese Clinical Trial Registry, ChiCTR-INR-16010063. Registered on 2 December, 2016 Keywords: Perennial allergic rhinitis, Chinese traditional medicine, Randomized controlled trial, Clinical efficacy

show abstract

Quality-of-Life Outcomes in Patients who Underwent Subcutaneous Immunotherapy and Sublingual Immunotherapy in a Real-World Clinical Setting

Cited by 15 publications

References 42 publications

Quality of life improvement with allergen immunotherapy treatment in patients with rhinoconjunctivitis in real life conditions. Results of an observational prospective study (ÍCARA)

Quality of life improvement with allergen immunotherapy treatment in patients with rhinoconjunctivitis in real life conditions. Results of an observational prospective study (ÍCARA)

Allergic reactions after vaccination: translating guidelines into clinical practice

Efficacy of Bimin Decoction on patients with perennial allergic rhinitis: an open-label non-inferiority randomized controlled trial

Contact Info

Product

Resources

About